CONMED Cash Flow Statement
NYSE: CNMDHealth CareBiotechnology: Electromedical & Electrotherapeutic ApparatusUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
CONMED free cash flow
In fiscal 2025, CONMED generated $170.7 million of operating cash flow and spent $19.8 million on capital expenditures. That left free cash flow of $150.9 million, a free-cash-flow margin of 11.0% of revenue. Free cash flow was down 2.0% from the prior year's $153.9 million.
CONMED returned $24.7 million to shareholders through dividends, equal to 16% of free cash flow. Free cash flow covered dividend payments 6.1 times.
Summary generated from market data by MetaCap's automated system. Methodology
CONMED cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 47.05M | 132.42M | 64.46M | -80.58M | 62.54M | 9.52M | 28.62M | 40.85M | 55.49M | 14.66M |
| Net Income growth (YoY) | -64.47% | +105.44% | — | -228.84% | +557.16% | -66.75% | -29.95% | -26.37% | +278.39% | -51.92% |
| Depreciation & Amortization | 17.14M | 16.61M | 16.20M | 16.05M | 16.49M | 18.04M | 18.69M | 18.53M | 20.08M | 20.48M |
| Stock-Based Compensation | 28.32M | 25.56M | 24.26M | 21.73M | 16.34M | 13.11M | 11.78M | 10.04M | 8.47M | 8.38M |
| Change in Working Capital | -25.81M | -36.70M | -50.08M | -88.46M | -65.09M | -24.14M | 66.51M | 33.85M | 10.08M | 25.22M |
| Operating Cash Flow | 170.69M | 166.97M | 125.35M | 33.37M | 111.77M | 64.53M | 95.13M | 74.70M | 65.57M | 39.88M |
| Capital Expenditures | -19.81M | -13.08M | -19.03M | -21.79M | -14.87M | -13.01M | -20.07M | -16.51M | -12.84M | -14.75M |
| Investing Cash Flow | -20.96M | -13.08M | -20.03M | -249.53M | -14.87M | -13.64M | -387.66M | -16.51M | -29.05M | -266.02M |
| Dividends Paid | -24.75M | -24.65M | -24.50M | -23.96M | -23.26M | -22.82M | -22.60M | -22.44M | -22.31M | -22.21M |
| Share Repurchases | — | — | — | — | — | — | — | — | — | 0 |
| Debt Issued | 25.23M | 0 | 0 | 0 | 52.41M | 0 | 265.00M | 0 | 0 | 175.00M |
| Debt Repaid | -99.82M | 0 | -20.00M | -92.98M | -66.65M | -13.25M | -154.31M | -13.13M | -8.75M | -8.75M |
| Financing Cash Flow | -135.82M | -151.00M | -110.43M | 225.00M | -101.55M | -52.06M | 300.88M | -72.27M | -34.88M | 182.54M |
| Net Change in Cash | 16.36M | 163.00K | -4.65M | 8.10M | -6.51M | 1.50M | 8.35M | -15.11M | 5.19M | -45.08M |
| Free Cash Flow | 150.88M | 153.88M | 106.32M | 11.58M | 96.90M | 51.52M | 75.07M | 58.19M | 52.72M | 25.13M |
This table shows 10 annual periods of CONMED's cash flow statement, from FY 2025 back to FY 2016, across 14 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow CNMD's reporting calendar. What is a cash flow statement?